Skip to main content
SpringerLink
Log in

Current Treatment Modalities in Advanced Colorectal Carcinoma

  • Conference paper
New Perspectives in Molecular and Clinical Management of Gastrointestinal Tumors

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 142))

Abstract

Several biochemical and immunological substances are currently being tested for their efficacy in the treatment of advanced colorectal cancer, the second-most malignant disease in the western world. Presently, a combination of 5-fluorouracil (FU) and the biochemical modulator folinic acid is considered to be the standard treatment for this malignancy, with a median response rate of 30%. A recent multi-analysis of phase III trials with methotrexate and FU versus FU alone has demonstrated a statistically significant doubling of the response rate as well as a significant survival advantage for the combination. So far, other biochemical or immunological modulators of FU have not shown a significant advantage regarding response or survival. Several new drugs such as tegafur, thymidilate synthase inhibitors, trimetrexate, or topoisomerase-I-inhibitors have been tested with promising results in preclinical and early clinical settings. While local treatment such as hepatic artery infusion has become safer, it is still more toxic than systemic treatment and showed a significant improvement of response but no survival advantage. Since all treatment strategies in advanced colorectal cancer are still palliative, quality of life is a more important endpoint in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aaronson NK, Ahmedzai S, Bullinger M (1993) The European Organisation for Research and Treatment of Cancer QLQ-C-30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 333–338

    Google Scholar 

  • Abad A, Rosell R, Pastor MC, Barnadas A, Caries J, Ribelles N. Oller B, Armengol M, Salva A, Ribas M (1991) Sequential combination of methotrexate (MTX), 5fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation? Am J Clin Oncol 14: 393–396

    PubMed  CAS  Google Scholar 

  • Abad A, Garcia P, Grâvalos C, Tusquets I, Rosell R, Perez-Manga G, Cortés-Funes H, Fabregat X, Barnadas A (1992) Phase-III trial with methotrexate, 5-FU and high-dose leucovorin (MFL) vs 5-FU, leucovorin (FL) vs 5-FU (F) in advanced and metastatic colorectal cancer. Proc Am Soc Clin Oncol 11: 161 (abstract)

    Google Scholar 

  • Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W (1991) A phase-I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491–498

    PubMed  CAS  Google Scholar 

  • Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rates. J Clin Oncol 10: 896–903

    Google Scholar 

  • Advanced Colorectal Cancer Meta-Analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12: 960–969

    Google Scholar 

  • Ahlgren JD, Lokich J, Schulz J, McCulloch W, Lynn J, Schein PS (1990) Protracted infusion of 5-fluorouracil (5-FU) with weekly PALA: pilot study in metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 9: 119 (abstract)

    Google Scholar 

  • Aiba K, Ogawa M, Kuraishi Y, Akazawa S, Sasaki T, Sakata Y, Esaki K (1993) A combination phase-II study of 5-fluorouracil and natural-type alpha interferon in patients with advanced colorectal adenocarcinoma. Proc Am Soc Clin Oncol 12: 208 (abstract)

    Google Scholar 

  • Ajani JA, Kanojia MD, Bedikian AY, Korinek JK, Stein SH, Espinoza EG, Bodey GP (1985) Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncol 8: 69–71

    PubMed  CAS  Google Scholar 

  • Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM (1988) Phase-II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs 6: 47–50

    PubMed  CAS  Google Scholar 

  • Ajani JA, Rios AA, Ende K, Abbruzzese JL, Edwards C, Faintuch JS, Saks S, Gutterman JU, Levin B (1989) Phase-I and -II studies of the combination of recombinant human interferon-y and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod 8: 140–146

    PubMed  CAS  Google Scholar 

  • Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase-II study. J Clin Oncol 12: 1821–1826

    PubMed  CAS  Google Scholar 

  • Anttila MI, Slotaniemi EA, Kairaluoma MI, Mokka RE, Sundquist AT (1983) Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10: 150–153

    PubMed  CAS  Google Scholar 

  • Arai Y, Kido C, Endo T, Miyake Y, Ariyoshi Y, Fukushima M (1988) Hepatic arterial infusion (HAI) chemotherapy for liver metastasis from colon, gastric and breast cancer (ca). Proc Am Soc Clin Oncol 7: 102 (abstr)

    Google Scholar 

  • Ardalan B, Glazer RI, Kensler TW, Jayaram HN, Pham TV, Macdonald JS, Cooney DA (1981) Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in a human mammary carcinoma. Biochem Pharmacol 30: 2045–2049

    PubMed  CAS  Google Scholar 

  • Ardalan B, Singh G, Silberman H (1988) A randomized phase-I and -II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-Laspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6: 1053–1058

    PubMed  CAS  Google Scholar 

  • Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A (1991) A phase-II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625–630

    PubMed  CAS  Google Scholar 

  • Au JL, Freidman MA, Sadeed W (1979) Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep 63: 343–350

    PubMed  CAS  Google Scholar 

  • Auber M, Lynch J, Higa G, Romero P, DeVore R, Crowell E, Rogers J, Raich P (1994) Phase-I study of 5-FU, folinic acid (FA), and recombinant interferon alpha-2 (IFN) in patients (pts) with metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 13: 209 (abstract)

    Google Scholar 

  • Balch CM, Urist MM, McGregor ML (1983) Continuous regional chemotherapy for metastatic colorectal cancer using a totally implantable infusion pump. Am J Surg 145: 285–290

    PubMed  CAS  Google Scholar 

  • Bang YJ, Kim HT, Suh CI, Kim SY, Heo DS, Kim NK (1992) Phase II study of 5fluorouracil and recombinant interferon-gamma in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 11: 179 (abstract)

    Google Scholar 

  • Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTCQLQ-LC 13: a modular supplement to the EORTC core quality-of-life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30: 635–642

    Google Scholar 

  • Boring CC, Squires TS, Tong T (1993) Cancer statistics, 1993. CA Cancer J Clin 43: 7–26

    PubMed  CAS  Google Scholar 

  • Botto HG, Galvez C, Palao Marco F, Bonamassa M, Fabeiro MA, Marin F, Botto IS (1992) 5-Fluorouracil (5-FU) and interferon alpha 2 b (INF) in advanced colo-rectal cancer: results in 47 patients. Proc Am Soc Clin Oncol 11:176 (abstract)

    Google Scholar 

  • Brunetti I, Falcone A, Bertuccelli M, Giannessi PG, Conte PF (1992) Double 5fluorouracil (5-FU) modulation with folinic acid (FA) and recombinant alfa 2-B interferon (IFN) in patients (PTS) with metastatic colorectal carcinoma (MCRC). Proc Am Soc Clin Oncol 11: 175 (abstract)

    Google Scholar 

  • Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DL, Laurie JA, Moon MD (1985) A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5fluorouraçil therapy in colorectal carcinoma. J Clin Oncol 3: 1624–1631

    PubMed  CAS  Google Scholar 

  • Buroker TR, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14–20

    PubMed  CAS  Google Scholar 

  • Buter J, Sinnige HAM, Cats A, Sleijfer DTh, Verschueren RCJ, Mulder NH (1994) Maintenance of remission on 5-fluorouracil (5-FU), leucovorin (LV) and α-2a interferon (IFNα) in advanced colorectal cancer. Proc Am Soc Clin Oncol 13: 193 (abstract)

    Google Scholar 

  • Cadman E, Heimer R, Benz C (1980) The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 256: 1695–1704

    Google Scholar 

  • Cantrell JE Jr, Brunet R, Lagarde C, Schein PS, Smith FP (1982) Phase-II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer. Cancer Treat Rep 66: 1563–1565

    PubMed  Google Scholar 

  • Cascinu S, Fedeli A, Luzi Fedeli L, Catalano G (1992) Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low-dose interferon alpha 2b in advanced colorectal cancer patients. Ann Oncol 3: 489–491

    PubMed  CAS  Google Scholar 

  • Cellerino R, Antognoli S, Giustini L, Acito L, Marcellin M, Bavosi M, Trivisonne R, Francini G, Del Papa M, Rossi G, Testa E, Latini L, Piga A (1994) A randomised study of fluorouracil (5FU) with or without α-interferon (IFN) in advanced colorectal cancer. Proc Am Soc Clin Oncol 13: 217 (abstract)

    Google Scholar 

  • Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM (1987) A prospective randomized trial of regional versus systemic continuous 5fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685–693

    PubMed  CAS  Google Scholar 

  • Clark PI, Slevin MK, Reznek RH, Niederle N, Kurschel E, Lundell G, Cedermark B, Fallenius A, Blomgren H, Ohman U, Silfersward C, Theve NO, Wrigley PFM (1987) Two randomized phase-II trials of intermittent intravenous versus subcutaneour a-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. Int J Colorect Dis 2: 26–29

    CAS  Google Scholar 

  • Clavel M, Vermorken JB, Judson I, Wagener T, Hatty S, Wanders J (1992) Gemcitabine is an active drug in patients with squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 11: 249 (abstract)

    Google Scholar 

  • Clendeninn NJ, Guaspari A, Laufman LR, Brenckman WD Jr, and the BW Colorectal Cancer Cooperative Group (1990) A randomized, double-blind trial of fluorouracil (FU) plus placebo (P) vs FU plus high dose oral leucovorin (LV) in colorectal cancer. J Cancer Res Clin Oncol 116 [Suppl part I1: 661 (abstract)

    Google Scholar 

  • Cohen AM, Kaufman SD, Wood WC, Greenfield AJ (1983) Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg 145: 529–533

    PubMed  CAS  Google Scholar 

  • Cohen AM, Schaeffer N, Higgins J (1986) Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy. Cancer 57: 1115–1117

    PubMed  CAS  Google Scholar 

  • Collins KD, Stark GR (1971) Aspartate transcarbamylase. Interaction with the transi- tion-state analogue N-(phosphonacetyl)-L-aspartate. J Biol Chem 246: 6599–6605

    Google Scholar 

  • Conti JA, Kemeny N, Seiter K, Goker E, Tong W, McKenzie A, Ragusa K, Bertino JR (1994) Trial of sequential trimetrexate, fluorouracil and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 12:695–700

    Google Scholar 

  • Corfu-A Study Group (1995) Phase-III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin in advanced colorectal caner. J Clin Oncol 13: 921–928

    Google Scholar 

  • Cortesi E, Aschelter AM, Marchetti P, Padovani A, Pellegrini A (1987) Three drugs treatment for regional intra-arterial therapy liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 6: 95 (abstr)

    Google Scholar 

  • Daniels J, Pentecost M, Teitelbaum G, Daniels A, Paylunian C, Sternlicht M (1992) Hepatic artery chemoembolization (HAE) for carcinoma of colon using angiostat collagen and cisplatin, mitomycin, and doxorubicin: response, survival, and serum levels. Proc Am Soc Clin Oncol 11: 171 (abstract)

    Google Scholar 

  • Delfino C, Gaccia G, Maniago O (1992) 5-Fluorouracil (FU) alone versus methotrexate (M) + leucovorin (L) + FU in patients (pts) with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 11:177 (abstract)

    Google Scholar 

  • Denck H (1984) Ergebnisse einer intraarteriellen intermittierenden Chemotherapie mit 5-FU bei Metastasenleber sowie inoperablen Tumoren des Gastrointestinal-und Urogenitaltrakts. Onkologie 7: 167–176

    PubMed  CAS  Google Scholar 

  • De Vecchis L, Nunziata C, Ricci F, Cucchiara G, Picconi A, Bonmassar G, Lagomarsino Caprino M, Bonmassar E (1989) Immunotherapy of advanced colorectal cancer with alpha-interferon and 5-fluorouracil. J Chemother 1: 128–135

    PubMed  Google Scholar 

  • Di Costanzo F, Bartolucci R, Calabresi F, Sofra M, Marzola M. Belsanti V, Boni C, Bacchi M (1992) Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research ( GOIRC ). Ann Oncol 3: 371–376

    Google Scholar 

  • Doroshow JH, Mullhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, Odujinrin O, Delap R, Shuster J, Newman E (1990) Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous-infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to dremotherapy. J Clin Oncol 8: 491–501

    PubMed  CAS  Google Scholar 

  • Douillard JY, Leborgne J, Danielou JY, Lehur PA, Poltron L, Le Neel JC, Bolze JL, Jutel P (1991) Phase-II trial of 5-fluorouracil (5 FU) and recombinant alpha interferon (R IFN) (Intron AR) in metastatic, previously untreated colorectal cancer (CRC). Proc Am Soc Clin Oncol 10: 139 (abstract)

    Google Scholar 

  • Dufour P, Husseini F, Cure P, Olivier JP, Dumas F, Dreyfuss F, Prevot G, Cholet Ph, Audhuy B, Oberling F (1992) Randomized study of 5-fluorouracil (5-FU) versus 5-FU + alpha 2A interferon (IFN) for metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 11: 192 (abstract)

    Google Scholar 

  • Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA (1982) Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection. J Natl Cancer Inst 68:227–231

    Google Scholar 

  • Erlichman C, Fine S. Wang A, Elkahim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469–475

    CAS  Google Scholar 

  • Fleischer DE, Goldberg SB, Browning TH, Cooper JN, Friedman E, Goldner FH, Keeffe EB, Smith LE (1989) Detection and surveillance of colorectal cancer. JAMA 261: 580–585

    CAS  Google Scholar 

  • Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49: 1621–1639

    PubMed  CAS  Google Scholar 

  • Friedman MA, Ignoffo RJ (1980) A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat Rev 7: 205–213

    PubMed  CAS  Google Scholar 

  • Gallo RC, Whang-Peng J, Adamson RH (1971) Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46: 789–795

    PubMed  CAS  Google Scholar 

  • Glimelius B, Ginman C, Graffman S, Pâhlman L, Stâhle E (1986) Sequential methotrexate-5-FU-leucovorin ( MFL) in advanced colorectal cancer. Eur J Cancer Clin Oncol 22: 295–306

    Google Scholar 

  • Glimelius B, Hoffmann K, Graf W, Pahlman L, Sjöden PO (1994) Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 73: 556–562

    PubMed  CAS  Google Scholar 

  • Goldberg JA, Kerr DJ, Wilmott N, McKillop JH, McArdle CS (1990) Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases. Br J Surg 77: 1238–1240

    PubMed  CAS  Google Scholar 

  • Graf W, Glimelius B, Pâhlman L, Bergström R (1991) Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 27: 1119–1123

    PubMed  CAS  Google Scholar 

  • Graf W, Pâhlman L, Bergström R, Glimelius B (1994a) The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 70: 559–563

    PubMed  CAS  Google Scholar 

  • Graf W, Bergström R, Pâhlman L, Glimelius B (1994b) Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 30A: 453–457

    Google Scholar 

  • Grage TB, Vassilopoulos PP, Shingleton WW, Jubert AV, Elias EG, Aust JB, Moss SE (1979) Results of a prospective randomized study of hepatic arterial infusion with 5fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a Central Oncology Group study. Surgery 86: 550–555

    PubMed  CAS  Google Scholar 

  • Grem JL, Hoth DF, Hamilton JM, King SA, Leyland-Jones B (1987) Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 71: 1249–1264

    PubMed  CAS  Google Scholar 

  • Grem JL, King SA, O’Dwyer PJ, Leyland-Jones B (1988) Biochemistry and clinical activity of N-(phosphonacetyl-L-aspartate: a review. Cancer Res 48: 4441–4454

    PubMed  CAS  Google Scholar 

  • Grem JL, McAtee N, Murphy RF, Balis FM, Steinberg SM, Hamilton JM, Sorensen JM, Sartor O, Kramer BS, Goldstein LJ, Gay LM, Caubo KM, Goldspiel B, Allegra CJ (1991) A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 9: 1811–1820

    PubMed  CAS  Google Scholar 

  • Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, Arbuck SG, Beveridge RA, Kales AN, Miller JA, Weiss RB, McAtee N, Chen A, Goldspiel B, Saver E, Allegra CJ (1993) Phase-II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 11: 1737–1745

    PubMed  CAS  Google Scholar 

  • Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon III. Evidence that IL2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158: 1356–1361

    PubMed  CAS  Google Scholar 

  • Hamblin TJ, Inzani V, Sadullah S, Stevenson FK, Williamson P, Van der Plas J, Palmer P, Franks CR (1989) A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma. Cancer Treat Rev 16 [Suppl A3: 163–167

    Google Scholar 

  • Hansen R, Ritch P, Anderson T (1986) Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma. Am J Clin Oncol 9: 352–354

    PubMed  CAS  Google Scholar 

  • Haskell CM, Selch MT, Ramming KP (1990) Colon and rectum. In: Haskell DM (ed) Cancer treatment. Saunders, Philadelphia, pp 232–254

    Google Scholar 

  • Heidelberger C, Chaudhari NK, Danenberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheirer J (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179: 663–666

    PubMed  CAS  Google Scholar 

  • Herrmann R, Spehn J, Beyer JH, von Franqué U, Schmieder A, Holzmann K, Abel U (1984) Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer. J Clin Oncol 2: 591–594

    PubMed  CAS  Google Scholar 

  • Herrmann R, Knuth A, Kleeberg U, Middeke H, Korsten FW, Trux FA, Schmieder A, Evers C (1992) Sequential methotrexate and 5-fluorouracil (5-FU) vs 5-FU alone in metastatic colorectal cancer. Ann Oncol 3: 539–543

    PubMed  CAS  Google Scholar 

  • Herrmann R, Mross K, Kleeberg U, Kreuser ED, Becher R, Edler L, Queißer W, Liati P, Kerpel-Fronius S for the Phase-II Study Group of the Association of Medical Oncology of the German Cancer Society (1995) 4’-Iodo-4’deoxydoxorubicin ( IDX) in colorectal cancer — a multicenter phase-II study. Onkologie 18: 28–30

    Google Scholar 

  • Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey JB (1990) Evaluation of the antitumor activity of gemcitabine (2’,2’-difluoro-2’deoxycytidine). Cancer Res 50: 4417–4422

    PubMed  CAS  Google Scholar 

  • Heys SD, Eremin O, Ruggeri EM, Pein F, Rainer H, Oskam R, de Peuter RA, Palmer PA, Franks CR (1995) A phase-III study of recombinant interleukin-2,5fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. Eur J Cancer 31A: 19–25

    Google Scholar 

  • Hilgenfeld RU, Kreuser ED (1996) Immunological and biochemical modulation in the treatment of advanced colorectal cancer: update and future directions. In: Güntbert U, Birchmeier W (eds) Attempts to understand metastasis formation. Springer, Berlin Heidelberg New York (Current Topics in Microbiology and immunology, vol 213/III)

    Google Scholar 

  • Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, Ignoffo RJ, Acord P, Lewis BJ (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7: 1646–1654

    PubMed  CAS  Google Scholar 

  • Huberman M, McClay E, Atkins M, Goldsweig H, Bonanno D, Layton M, Tessitore J (1991) Phase-II trial of 5 fluorouracil (5FU) and recombinant interferon-a-2a (IFN) in advanced colorectal cancer. Proc Am Soc Clin Oncol 10: 153 (abstract)

    Google Scholar 

  • Inoshita G, Yalavarthi P, Murthy S, Budd GT, Andresen S, Netaji B, Gibson V, Sergi J, Bukowski RM (1991) Phase-I trial of 5-FU, leucovorin (LV) and rHuIFN-alpha2a in metastatic colorectal cancer (CR Ca). Proc Am Soc Clin Oncol 10: 152 (abstract)

    Google Scholar 

  • Itri LM (1992) The interferons. Cancer 70: 950–945

    Google Scholar 

  • Jaiyesimi I, Pazdur R, Patt YZ, Ajani J, Abbruzzese JL, Daugherty K, Levin B (1991) Phase-II study of recombinant interferon alpha 2a (rIFN) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 10: 147 (abstract)

    Google Scholar 

  • John W, Neefe J, Smith M, Massie M, Cantrell J (1992) 5-Fluorouracil (5-FU) and interferon-a (IFN) in advanced colon cancer: The University of Kentucky experience. Proc Am Soc Clin Oncol 11:189 (abstract)

    Google Scholar 

  • Johnson LP, Rivkin SE (1985) The implanted pump in metastatic colorectal cancer of the liver. Risk versus benefit. Am J Surg 149: 595–598

    Google Scholar 

  • Kemeny NE (1992) Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 207–227

    Google Scholar 

  • Kemeny N, Braun DW (1983) Prognostic factors in advanced colorectal carcinoma. Am J Med 74: 786–794

    PubMed  CAS  Google Scholar 

  • Kemeny NE, Ahmed T, Michaelson RA, Harper HD, Yip LC (1984a) Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phophoribosylpyrophosphate. J Clin Oncol 2: 311–315

    PubMed  CAS  Google Scholar 

  • Kemeny N, Daly J, Oderman P, Shike M, Chun H, Petroni G, Geller N (1984b) Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 2: 595–600

    PubMed  CAS  Google Scholar 

  • Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Int Med 107: 459–465

    Google Scholar 

  • Kemeny NE, Reichman B, Geller N, Hollander P (1988) Implementation of the group sequential methodology in a randomized trial in metastatic colorectal carcinoma. Am J Clin Oncol 6: 84 (abstract)

    Google Scholar 

  • Kemeny N, Younes A, Seiter K, Kelsen D, Sammarco P, Adams L, Derby S, Nurray P, Houston C (1990) Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 66: 2470–2475

    Google Scholar 

  • Kemeny N, Costa JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W (1992a) Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. J Clin Oncol 10: 747–752

    PubMed  CAS  Google Scholar 

  • Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, Botet J, Oderman P (1992b) A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 69: 327–334

    PubMed  CAS  Google Scholar 

  • Kemeny N, Cohen A, Seiter K, Conti JA, Sigurdson ER, Tao Y, Niedzwiecki D, Botet J, Budd A (1993) Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 11: 330–335

    PubMed  CAS  Google Scholar 

  • Kemeny N, Conti JA, Cohen A, Campana P, Huang Y, Shi WJ, Botet J, Pulliam S, Bertino JR (1994) Phase II study of hepatic artery floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12: 2288–2295

    PubMed  CAS  Google Scholar 

  • Kennett RH, Jonak ZL, Bechtol KB (1980) Monoclonal antibodies against human tumor-associated antigens. In: Kennett RH, McKearn TJ, Bechtol KB (eds) Monoclonal antibodies: hybridomas: a new dimension in biological analyses. Plenum, New York, pp 55–168

    Google Scholar 

  • Köhne-Wömpner CH, Schmoll HJ, Hiddemann W, Knipp H, Wilke H, Bodenstein H, Lohrmann HP, Preiss J, Käufer C, Fischer JT, Balleisen L, Urbanitz D, Schwark J, Schöffski P, Kreuser ED, Graubner M (1991) 5-Fluorouracil (5-FU), leucovorin (LV), alpha-2b interferon (IFN) in advanced colorectal cancer (CC): a phase-I/II study. Proc Am Soc Clin Oncol 10:159 (abstract)

    Google Scholar 

  • Kosmidis P, Tsavaris N, Skarlos D, Pavlidis N, Beer M, Theocharis D, Samanta D, Briasoulis E, Fountzilas G (1993) Fluorouracil (5-FU) and folinic acid (FA) with or without a2b-interferon (IFN) in advanced colorectal cancer (ACC). A prospective randomized trial. Proc Am Soc Clin Oncol 12: 211 (abstract)

    Google Scholar 

  • Kreuser ED, Hilgenfeld RU, Matthias M, Hoksch B, Boewer C, Oldenkott B, Knauf WU, Boese-Landgraf J, Schalhorn A, Zeitz M, Thiel E (1992a) A phase-I trial of interferon a-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. Semin Oncol 19 [Suppl 31: 197–203

    Google Scholar 

  • Kreuser ED, Wadler S, Thiel E (1992b) Interactions between cytokines and cytotoxic drugs: Putative molecular mechanisms in experimental hematology and oncology. Semin Oncol 19 [Suppl 4]: 1–7

    PubMed  CAS  Google Scholar 

  • Kreuser ED, Hilgenfeld RU, Matthias M, Hoksch B, Boewer C, Oldenkott B, Lenk H, Wiener N, Boese-Landgraf J, Schalhorn A, Thiel E (1992c) A phase-II trial of interferon a-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. Semin Oncol 19 [Suppl 4]: 57–62

    PubMed  CAS  Google Scholar 

  • Kreuser ED, Streit M, Kuchler T, Matthias M, Thiel E (1995) A multicenter randomized trial with the assessment of the quality of life in patients with metastatic colorectal carcinoma given either folinic acid or interferon a-2b as a modulator of 5fluorouracil. Proc Am Soc Clin Oncol 14: 202 (abstract)

    Google Scholar 

  • Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944–5947

    PubMed  CAS  Google Scholar 

  • Labianca R, Pancera G, Luporini A, Dallavalle G, Locatelli MC, Fraschini P, Luporini G (1990) Double modulation of 5-fluorouracil (5-FU) with alb interferon (IFN) and folinic acid (FA) in advanced colorectal cancer. Ann Oncol 1 (Suppl): 92 (abstract)

    Google Scholar 

  • Labianca R, Pancera G, Aitini E, Barrai S, Beretta A, Beretta GD, Cesana B, Comella G, Cozzaglio L, Cristoni M, Spagnolli P, Frontini L, Gottardi O, Martignoni G, Scapaticci R, Smerieri F, Vinci M, Zadro A, Zaniboni A, Luporini G (1991) Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase-III study of “GISCAD” ( Italian Group for the Study of Digestive Tract Cancer ). Ann Oncol 2: 673–679

    Google Scholar 

  • Labianca R, Giaccon G, Pancera G, Ambrosini G, Amichetti G, Barai S, Cascinu S, Martignoni G, Pavananto G, Scapaticci R, Zaniboni A, Luporini G (1992) Low-dose alb interferon (IFN) + folinic acid (FA) + 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): a phase-II study of GISCAD (Italian Group for the Study of Gastrointestinal Cancer). Proc Am Soc Clin Oncol 11: 177 (abstract)

    Google Scholar 

  • Lang EK, Brown CL (1993) Colorectal metastases to the liver: selective chemoembolization. Radiology 189: 417–422

    PubMed  CAS  Google Scholar 

  • Lembersky B, Koff H, Miketic L, Posner M, Jacobs S, Carr B (1992) Phase-II trial of 5-fluorouracil (FU), leucovorin (LV) and interferon alfa-2b (IFN) in the treatment of metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 11: 186 (abstract)

    Google Scholar 

  • Leone BA, Romero A, Rabinovich MG, Perez JE, Macchiavelli M, Strauss E (1986) Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma. J Clin Oncol 4: 23–27

    PubMed  CAS  Google Scholar 

  • Leone B, Romero A, Rabinovich M, Vallejo C, Bianco A, Perez J, Rodriguez R, Cuevas A, Macchiavelli M, Paris A, Lacava J (1992) Double modulation of 5fluorouracil (5-FU) by methotrexate (MTX) and leucovorin (LV) in metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 11: 174 (abstract)

    Google Scholar 

  • Lorenz M, Maier P, Reimann M, Inglis R, Hottenrott C (1992) Regionale Chemotherapie von 160 Patienten mit Lebermetastasen kolorektaler Karzinome. In: Schmoll HJ, Meyer HJ, Wilke H, Pichlmayer R (eds) Aktuelle Therapie gastrointestinaler Tumoren, 1st edn. Springer, Berlin Heidelberg New York, pp 372–381

    Google Scholar 

  • Macchiavelli M, Leone B, Romero A, Rabinovich M, Vallejo C, Bianco A, Pérez J, Rodriguez R, Cuevas M, Alvarez L, Chacon R, Hannois A (1990) Advanced colorectal carcinoma (CRC): a prospective randomized trial of sequential methotrexate (MTX) — 5-fluorouracil (5FU) vs. 5FU alone. Proc Am Soc Clin Oncol 9: 102 (abstract)

    Google Scholar 

  • Marsh JC, Bertino JR, Katz KH, Davis CA, Durivage HJ, Rome LS, Richards F 2nd, Capizzi RL, Farber LR, Pasquale DN, Stuart R, Koletsky AJ, Makuch R, O’Hollaren K (1991) The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9: 371380, 1991

    Google Scholar 

  • Martin DS, Kemeny NE (1992) Modulation of fluorouracil by N-(phosphonacetyl)-Laspartate: a review. Semin Oncol 19: 49–55

    PubMed  CAS  Google Scholar 

  • Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Casper ES, Young CW (1983) Therapeutic utility of utilizing low-dose N-(phosphonacetyl)-L aspartic acid in cornbination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res 43: 2317–2321

    PubMed  CAS  Google Scholar 

  • Martin JK Jr, O’Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, Nagorney DM, Tschetter LK, Krook JE (1990) Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125: 1022–1027

    Google Scholar 

  • Martinelli DJ, Wadler S, Bakal CW, Cynamon J, Rozenblit A, Haynes H. Kaleya R, Wiernik PH (1994) Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 74: 1706–1712

    PubMed  CAS  Google Scholar 

  • Matsuoka H, Furasawa M, Tomoda H, Seo Y, Kono A, Takeda S, Sato K (1994) Cytotoxicity of CPT-11 and SN-38 for gastrointestinal and recurrent carcinomas cultured on contract-sensitive plates. Anticancer Res 14: 405–409

    PubMed  CAS  Google Scholar 

  • Meehan K, Seidler C, Gehr G, Maurer LM (1993) An outpatient regimen of 5fluorouracil (5-FU) and recombinant interferon alpha-2b (rlFNa-2B) in metastatic adenocarcinoma of the colon (MAC). Proc Am Soc Clin Oncol 12: 222 (abstract)

    Google Scholar 

  • Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352–358

    PubMed  CAS  Google Scholar 

  • Moertel C, Fleming T, Macdonald J, Haller D, Laurie J (1992) The intergroup study of fluorouracil (5-FU) plus levamisole (LEV) and levamisole alone as adjuvant therapy for stage C colon cancer. Proc Am Soc Clin Oncol 11: 161 (abstract)

    Google Scholar 

  • Moore MJ, Kaizer L, Erlichman C, Bunting P, Feld R, Fine S, Myers R, Thiessen JJ, Yuan S (1992) A phase-II clinical and pharmacologic study of 5-fluorouracil (5FU) + leucovorin + interferon in advanced colorectal cancer. Proc Am Soc Clin Oncol 11: 183 (abstract)

    Google Scholar 

  • Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007–1010

    PubMed  CAS  Google Scholar 

  • Mross K, Mayer U, Hamm K, Burk K, Hossfeld DK (1990) Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans. Eur J Clin Pharmacol 39: 507–513

    PubMed  CAS  Google Scholar 

  • Muggia FM, Camacho FJ, Kaplan BH, Green MD, Greenwald ES, Wernz JC, Engstrom PF (1987) Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. Cancer Treat Rep 71: 253–256

    PubMed  CAS  Google Scholar 

  • Negoro S, Fukuoka M, Kurita Y, Niitani H (1994) Results of phase-II studies of gemcitabine in non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 13: 367 (abstract)

    Google Scholar 

  • Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E (1984) Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53: 1336–1343

    PubMed  CAS  Google Scholar 

  • Nobile MT, Rosso R, Sertoli MR, Rubagotti A, Vidili MG, Guglielmi A, Venturini M, Canobbio L, Fassio T, Gallo L, Galligioni E, Galotti P, Bruzzi P, Sobrero A (1992) Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 28A: 1823–1827

    Google Scholar 

  • Nordic Gastrointestinal Tumor Adjuvant Therapy Group (1989) Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol 7: 1437–1446

    Google Scholar 

  • O’Connell M, Poon MA, Wieand H, Moertel C, Krook J, Gerstner J (1990) Biochemical modulation of 5-fluorouracil (5FU) with leucovorin (LV): confirmatory evidence of improved therapeutic efficacy in the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 9: 106 (abstract)

    Google Scholar 

  • O’Dwyer PJ, DeLap RJ, King SA et al, (1987) Trimetrexate: clinical development of a nonclassical antifolate. NCI Monogr 5: 105–109

    PubMed  Google Scholar 

  • O’Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL (1990) Phase-II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8: 1497–1503

    PubMed  Google Scholar 

  • Ortaldo JR, Mason AT, Gerard JP, Henderson LE, Farrar W, Hopkings RF 3d, Herberman RB, Rabin H (1984) Effects of natural and recombinant IL2 on regulation of IFN gamma production and natural killer cell activity: lack of involvement of the TAC antigen for these immunoregulatory effects. J Immunol 133: 779–783

    PubMed  CAS  Google Scholar 

  • Panasci L, Ford J, Margolese R (1985) A phase-II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. Cancer Chemother Pharmacol 15:164–166

    Google Scholar 

  • Patt YZ, Mavligit GM (1991) Arterial chemotherapy in the management of colorecal cancer: an overview. Semin Oncol 18: 478–490

    PubMed  CAS  Google Scholar 

  • Patt YZ, Jones D, Chase J, Charnsangavej C, Chuang V, Carrasco H, Lawrence D, Roh M (1994) Hepatic arterial infusion (HAI) of recombinant intefereon-alpha (rIFNa) & 5-fluorouracil (5FU) for colorectal cancer (CRC) liver metastases refractory to intravenous (IV) 5FU & leucovorin (LCV). Proc Am Soc Clin Oncol 13: 201 (abstract)

    Google Scholar 

  • Pavlick AC, DelGaudio D, Harper H, Rosenbluth R, Pecora AL (1992) Salvage therapy with continuous infusion 5-fluorouracil and alpha interferon in patients with colorectal cancer. Proc Am Soc Clin Oncol 11: 188 (abstract)

    Google Scholar 

  • Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, Abbruzzese JL, Gutterman J, Levin B (1990) Phase-II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8: 2027–2031

    PubMed  CAS  Google Scholar 

  • Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B (1993) Phase-II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 71: 1214–1218

    PubMed  CAS  Google Scholar 

  • Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese JL, Bready B, Levin B (1994) Phase -II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 2296–2300

    PubMed  CAS  Google Scholar 

  • Pazdur R, Roach R, Braud E, Osmon C, Verschraegen C, Kolbye S, Bready B, Winn R (1994) Phase-II study of folinic acid, 5-fluorouracil,and interferon alfa-2a for patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 13: 224 (abstract)

    Google Scholar 

  • Pensel R (1993) Advanced colon cancer (ACC): a randomized trial of fluorouracil (5-FU) + folinic acid (FA) and 5-FU + FA + interferon alpha 2b (IFN). Proc Am Soc Clin Oncol 12: 203 (abstract)

    Google Scholar 

  • Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich LJ, Mittelman A (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559–1565

    PubMed  CAS  Google Scholar 

  • Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kaiser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase-III trial. J Clin Oncol 7: 1419–1426

    PubMed  CAS  Google Scholar 

  • Piedbois P, Gimonet JF, Feuilhade F, Le Péchoux C, Lévy C, Brun B, Rotman N, Delchier JC, Blasquez M, Thill L, Fagniez PL, Bader JP, Julien M, Le Bourgeois JP (1991) 5FU, folinic acid and alpha-2a-interferon combination in advanced gastrointestinal cancer. Proc Am Soc Clin Oncol 10:141 (abstract)

    Google Scholar 

  • Poon MA, O’Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1418

    PubMed  CAS  Google Scholar 

  • Presant CA, Ardalan B, Multhauf P, Chan C, Staples R, Green L, Browning S, Carr BI, Chang FF, Thayer W (1983) Continuous five-day infusion of PALA and 5FU: a pilot phase-II trial. Med Pediatr Oncol 11: 162–163

    PubMed  CAS  Google Scholar 

  • Punt CJA, de Mulder PHM, Burghouts JTM, Wagener DJT (1992) Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer. Semin Oncol 19 [Supp] 4208–210

    Google Scholar 

  • Pyrhönen SO, Kouri MO (1992) Phase-II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer. Eur J Cancer 28A: 1828–1832

    Google Scholar 

  • Quagliuolo V, Bignami P, Doci R, Civalleri D, Cosimelli M (1987) Continuous artery infusion of floxuridine for metastatic colorectal cancer. Proc ECCO 4: 179 (abstr)

    Google Scholar 

  • Recchia F, Nuzzo A, Lombardo M, Lalli A, Fabiani F, Fanini R, Di Lullo L, Venturoni L, Peretti G for the IORAM (Istituto Oncologico Regione Abruzzo e Molise) (1992) 5-Fluorouracil (5FU) and high-dose folinic acid (HDFA) chemotherapy (CT) with or without alfa 2b interferon (IFN) in advanced colorectal cancer (ACC). Preliminary report of a randomized trial. Proc Am Soc Clin Oncol 11:162 (abstract)

    Google Scholar 

  • Rios A, Levi B, Ajani J, Abbruzzese J, Faintuch J, Ende K, Gutterman J (1987) Combination of recombinant human interferon gamma (rIFN-a) and 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma (CRC). Proc Am Soc Clin Oncol 6: 84 (abstract)

    Google Scholar 

  • Romanini A, Li WW, Colofiore JR, Bertino JR (1992) Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J Natl Cancer Inst 84: 1033–1038

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson GN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485

    PubMed  CAS  Google Scholar 

  • Rougier P, Lasser P, Elias D, Ghosn M, Droz JP, Sidibe S, Theodore C, Lumbroso J (1987) Intra-arterial hepatic chemotherapy (IAHC) for liver metastases (LM) from colo-rectal (CR) origin. Proc Am Soc Clin Oncol 6: 94 (abstr)

    Google Scholar 

  • Rougier P, Ducreux M, Pignon JP, Elias D, Tigaud JM, Lumbroso J, Ruffle P, Lasser PH (1991) Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. Eur J Cancer 27: 1226–1230

    PubMed  CAS  Google Scholar 

  • Rougier P, Laplanche A, Huguier M, Hay JM, 011ivier JM, Escat J, Salmon R, Julien M, Roullet Audy JC, Gallot D, Gouzi JL, Pailler JL, Elisa D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P (1992) Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10: 1112–1118

    PubMed  CAS  Google Scholar 

  • Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP (1991) Regionale Chemotherapie bei diffusen Lebermetastasen des kolorektalen Karzinoms. Zenntralbl Chir 116: 1215–1235

    CAS  Google Scholar 

  • Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306: 752–755

    CAS  Google Scholar 

  • Schlag P, Hohenberger P, Schwarz V, Herfarth CH (1988) Intraarterielle 5-Fluorouracil-Chemotherapie bei Lebermetastasen kolorektaler Karzinome. Med Klin 83: 705–709

    CAS  Google Scholar 

  • Schwartz SI, Jones LS, McCune CS (1985) Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. Ann Surg 201: 560–567

    PubMed  CAS  Google Scholar 

  • Seymour MT, Johnson PWM, Wrigley PFM, Slevin ML (1991) 5-Fluorouracil (5FU), leucovorin (LV) and a-interferon (IFNa.): a new regimen suitable for randomised trial. Proc Am Soc Clin Oncol 10:160 (abstract)

    Google Scholar 

  • Seymour MT, Slevin M, Cunningham D, Kerr D, James R, Lederman J, Perren T, McAdam W, Duffy A, Stenning S, Taylor I (1994) A randomized assessment of interferon-a2a (IFNa) as a modulator of 5-fluorouracil (5FU) and leucovorin (LV) in advanced colorectal cancer. Proc Am Soc Clin Oncol 13: 209 (abstract)

    Google Scholar 

  • Shepard KV, Levin B, Karl RC, Faintuch J, DuBrow RA, Hagle M, Cooper RM, Beschorner J, Stablein D (1985) Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 3: 161–169

    PubMed  CAS  Google Scholar 

  • Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N, and the CPT-11 Gastrointestinal Cancer Study Group (1993) Phase-II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909–913

    Google Scholar 

  • Sinnige HAM, Sleijfer DT, de Vries EGE, Willemse PHB, Mulder NH (1990) Modification of 5-fluorouracil activity by high-dose methotrexate or leucovorin in advanced colorectal carcinoma. Eur J Cancer 26: 625–628

    PubMed  CAS  Google Scholar 

  • Sinnige HAM, Buter J, Sleijfer DTh, Verschueren RCJ, Mulder NH (1993) Update of a phase-II study of 5-fluorouracil (5-FU), leucovorin (LV) and a-2a interferon (IF) in advanced colorectal cancer. Proc Am Soc Clin Oncol 12: 206 (abstract)

    Google Scholar 

  • Sobrero A, Nobile MT, Guglielmi A, Mori A, Aschele C, Bolli E, Tixi L, Gallo L, Parodi GC, Bruzzi P, Brema F, Rosso R (1992) Phase-II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer. Eur J Cancer 28A: 850–852

    Google Scholar 

  • Sotos GA, Grogan L, Allegra CJ (1994) Preclinical and clinical aspects of bio-modulation of 5-fluorouracil. Cancer Treat Rev 20: 11–49

    PubMed  CAS  Google Scholar 

  • Stagg RJ, Venook AP, Chase JL, Lewis BJ, Warren RS, Roh M, Mulvihill SJ, Grobman BJ, Rayner AA, Hohn DC (1991) Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 83: 423–428

    PubMed  CAS  Google Scholar 

  • Steinberg J, Erlichman C, Gadalla T, Fine S, Wong A (1992) Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 28A: 1817–1820

    Google Scholar 

  • Steinke B, Günther E, Hirschmann WD, Sondern W, Koniczek KH, Wander HE, Natt F, Wagner T, Hinrichs HF, Werdier D (1992) Fluorouracil versus folinic acid/ fluorouracil in advanced colorectal cancer — preliminary results of a randomized trial. Semin Oncol 19 [Suppl 3]: 141–147

    PubMed  CAS  Google Scholar 

  • Taylor C, Modiano M, Alberts D, Marcus S, Hersh E (1991) Combination chemotherapy with 5-fluorouracil (5-FU), leucovorin (LCV) and interferon-alpha (IFN-a) in patients with adenocarcinoma. Proc Am Soc Clin Oncol 10: 141 (abstract)

    Google Scholar 

  • Thirlwell MP, Hollingsworth LM, Herba MJ, Boileau G, Boos G, MacFarlane JK (1986) Ambulatory hepatic artery infusion chemotherapy for cancer of the liver. Am J Surg 151: 585–589

    PubMed  CAS  Google Scholar 

  • Valone FH, Friedman MA, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, Hannigan JF, Brown BW Jr (1989) Treatment of patients wtih advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 7: 1427–1436

    PubMed  CAS  Google Scholar 

  • Van Hazel GA, Buck M, Byrne MJ (1992) Phase-II study of the combination of 5-fluorouracil (5FU), folinic acid (FA) and alpha interferon (IFN) in metastatic colorectal adenocarcinoma (CC). Proc Am Soc Clin Oncol 11: 195 (abstract)

    Google Scholar 

  • Villa R, Zaffaroni N, Giulani FC, Colella G, Sanfilippo O, Sivestrini R (1990) Absolute and relative activities of 4’-iodo-4’-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay. Anticancer Res 10: 105–108

    PubMed  CAS  Google Scholar 

  • Vogel VG, McPherson RS (1989) Dietary epidemiology of colon cancer. Hematol Oncol Clin North Am 3: 35–63

    PubMed  CAS  Google Scholar 

  • Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH (1989) Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769–1775

    PubMed  CAS  Google Scholar 

  • Wadler S, Lemebrsky B, Atkins M, Kirkwood J, Petrelli N (1991) Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 9: 1806–1810

    PubMed  CAS  Google Scholar 

  • Wadler S, Tenteromano L, Cazenave L, Sparano JA, Greenwald ES, Rozenblit A, Kaleya R; Wiernik PH (1994) Phase-II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother Pharmacol 34: 266–269

    PubMed  CAS  Google Scholar 

  • Weh HJ, Platz D, Braumann D, Buggisch P, Eckardt N, Schmiegel WH, Drescher S, Kleeberg UR, Müllerleile U, Crone-Munzebrock W, Hoffmann R, Müller P, Klapdor R, Pompecki R, Erdmann H, Reichel L, Jungbluth M, Hoffmann L, Mainzer K, Hossfeld DK (1992) Phase-II trial of 5-fluorouracil and recombinant interferon alfa-2b in metastatic colorectal carcinoma. Eur J Cancer 28A: 1820–1823

    Google Scholar 

  • Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld RU, Steinke B, Weber W, Burkhard O, Zoller A, Pfitzner J, Subert R, Kriebel R, Hossfeld DK (1994) Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 5: 233–237

    PubMed  CAS  Google Scholar 

  • Weinerman B, Schacter B, Schipper H, Bowman D, Levitt M (1982) Sequential methotrexate and 5-FU in the treatment of colorectal cancer. Cancer Treat Rep 66: 1553–1555

    PubMed  CAS  Google Scholar 

  • Weiss GR, Ervin TJ, Meshad MW, Kufe DW (1982) Phase-II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. Cancer Treat Rep 66: 299–303

    PubMed  CAS  Google Scholar 

  • Weiss GR, Garnick MB, Osteen RT, Steele GD Jr, Wilson RE, Schode D, Kaplan WD, Boxt LM, Kandarpa K, Mayer RJ, Frei ET III (1983) Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol 1: 337–344

    PubMed  CAS  Google Scholar 

  • Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Home CH, Lopez MJ (1986) Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 150: 195–203

    PubMed  CAS  Google Scholar 

  • Wils J, Schlangen J, Naus A (1986) Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C ( FAM) in liver metastases from colorectal carcinoma. Recent Results Cancer Res 100: 157–162

    Google Scholar 

  • Yang JC, Shlasko E, Ritchey JL, Landry JG, White DE, Rosenberg SA (1993) Combination chemotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. Eur J Cancer 29A: 355–359

    Google Scholar 

  • York M, Greco FA, Figlin RA, Einhorn L, Man T, Cockey L, Mott D, Light SE (1993) A randomized phase III trial comparing 5-FU with or without interferon alfa 2a for advanced colorectal cancer. Proc Am Soc Clin Oncol 12: 200 (abstract)

    Google Scholar 

  • Young JC, Shlasko E, Ritchey JL, Landry JG, White DE, Rosenberg SA (1993) Combination chemotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. Eur J Cancer 29A: 355–359

    Google Scholar 

  • Zalcberg J, Cunningham D, Green M, Francois E, van Cutsem E, Schornagel J, Adenis A, Seymour L, Azab M (1995) The final results of a large phase II study of the potent thymidilate synthase (TS) inhibitor Tomudex (ZD1694) in advanced colorectal cancer. Proc Am Soc Clin Oncol 14: 204 (abstr)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department I, St. Joseph Hospital, Bäumerplan 24, 12101, Berlin, Germany

    R. U. Hilgenfeld

  2. Department of Hematology/Oncology, University Medical Center Benjamin Franklin, Free University of Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    M. Streit, E. Thiel & E.-D. Kreuser

Authors
  1. R. U. Hilgenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Streit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Thiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E.-D. Kreuser
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fachbereich Humanmedizin, Univ.-Klinikum Benjamin Franklin, Medizinische Klinik und Poliklinik, Schwerpunkt Hämatologie und Onkologie, Freie Universität Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    Ernst-D. Kreuser

  2. Robert-Rössle Klinik am Max-Delbrück-Centrum, Humboldt-Universität, Lindenberger Weg 80, 13122, Berlin, Germany

    P. M. Schlag

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hilgenfeld, R.U., Streit, M., Thiel, E., Kreuser, ED. (1996). Current Treatment Modalities in Advanced Colorectal Carcinoma. In: Kreuser, ED., Schlag, P.M. (eds) New Perspectives in Molecular and Clinical Management of Gastrointestinal Tumors. Recent Results in Cancer Research, vol 142. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80035-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80035-1_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-80037-5

  • Online ISBN: 978-3-642-80035-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation